Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that 2 adalimumab biosimilars be treated as equivalent to the reference adalimumab, Humira, and be subject to substitution at the pharmacy level.
Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that 2 adalimumab biosimilars be treated as equivalent to the reference adalimumab, Humira, and be subject to substitution at the pharmacy level.
The products, Amgen’s Amgevita and Samsung Bioepis’ Hadlima, will be “a-flagged,” or given a listing that allows them to be substituted for Humira—or for one another—by a pharmacist for the indications that they share, although the prescribing physician retains the right to prevent substitution by requiring a prescription to be dispensed as written.
Read more about biosimilars in Australia.
In the case of Amgevita, which is approved for all indications of the reference product, a pharmacist could substitute Amgevita for Humira or Hadlima. In the case of Hadlima, which is only approved to treat rheumatoid arthritis (RA), Hadlima could be substituted by the pharmacist for either Humira or Amgevita to treat RA only.
Furthermore, the PBAC recommended that Australia’s “uptake drivers” be applied to adalimumab in the same way that they have been applied to etanercept and infliximab. The uptake drivers are policies that encouraging prescribing of biosimilars over branded drugs for new patients and that provide a faster and simpler preapproval process for patients to receive a biosimilar drug than a branded drug.
As part of the uptake driver process, the Australian government publishes fact sheets on the biosimilars, with separate documents made available to prescribers, pharmacists, and patients or their caregivers.
Australia’s approach to promoting biosimilar uptake through “a-flagging” biosimilars for substitution stands in contrast to the strategies used in the United States and Europe. In the United States, pharmacy-level substitution will only be permissible by law for products that gain the FDA’s designation of interchangeability (final guidance on which is yet to be published), and rules governing substitution will vary among US states according to local laws. In Europe, pharmacy-level substitution is, for the most part, forbidden; Estonia, France, Latvia, Poland, and Russia are notable exceptions.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.